Gestavet HCG 40 IU/ml / PMSG 80 IU/ml Lyophilisate and Solvent for Solution for Injection for Pigs

Երկիր: Միացյալ Թագավորություն

Լեզու: անգլերեն

Աղբյուրը: VMD (Veterinary Medicines Directorate)

Ակտիվ բաղադրիչ:

Chorionic Gonadotrophin, Serum Gonadotrophin

Հասանելի է:

Laboratorios Hipra SA

ATC կոդը:

sQG03GA9

INN (Միջազգային անվանումը):

Chorionic Gonadotrophin, Serum Gonadotrophin

Դեղագործական ձեւ:

Lyophilisate and solvent for solution for injection

Ռեկվիզորի տեսակը:

POM-V - Prescription Only Medicine – Veterinarian

Թերապեւտիկ խումբ:

Pigs

Թերապեւտիկ տարածք:

Hormone sex

Լիազորման կարգավիճակը:

Authorized

Հաստատման ամսաթիվը:

2009-12-16

Ապրանքի հատկությունները

Revised: April 2015
AN. 01586/2013
Page 1 of 5
SUMMARY OF PRODUCT CHARACTERISTICS
1.
NAME OF THE VETERINARY MEDICINAL PRODUCT
GESTAVET HCG 40 IU/ML / PMSG 80 IU/ML lyophilisate and solvent for
solution for
injection for pigs.
2.
QUALITATIVE AND QUANTITATIVE COMPOSITION
Liophilisate vial contains:
ACTIVE SUBSTANCES
Equine Serum Gonadotrophin (PMSG)...............2000 IU
Chorionic Gonadotrophin (HCG) .........................1000 IU
EXCIPIENTS, q.s
Solvent vial (25 ml) contains :
EXCIPIENTS, q.s.
One ml of reconstituted solution contains:
ACTIVE SUBSTANCES
Equine Serum Gonadotrophin (PMSG)...................80 IU
Chorionic Gonadotrophin (HCG) .............................40 IU
EXCIPIENTS, q.s.
Each reconstituted 5 ml dose contains:
ACTIVE SUBSTANCES
Equine Serum Gonadotrophin (PMSG).................400 IU
Chorionic Gonadotrophin (HCG) ...........................200 IU
EXCIPIENTS, q.s.
For the full list of excipients, see section 6.1.
3.
PHARMACEUTICAL FORM
Lyophilisate and solvent for solution for injection.
White, fragile, lyophilisate with clear, colourless solution.
Revised: April 2015
AN. 01586/2013
Page 2 of 5
4.
CLINICAL PARTICULARS
4.1
TARGET SPECIES
Pigs (sows).
4.2
INDICATIONS FOR USE, SPECIFYING THE TARGET SPECIES
SOWS: Induction and synchronization of heat.
4.3
CONTRAINDICATIONS
Do not use in animals with known hypersensitivity to the active
substances or to any of
the excipients.
Do not use in sows with polycystic ovaries.
Do not use in pregnant animals.
4.4
SPECIAL WARNINGS FOR EACH TARGET SPECIES
Treatment during the primary luteinized phase or in the middle of the
cycle may
increase the development of ovarian cysts.
The administration of this veterinary medicinal product induces heat
between 3 and 6
days after treatment.
Do not adjust the dose. High doses do not increase the efficacy of the
veterinary
medicinal product.
4.5
SPECIAL PRECAUTIONS FOR USE
Special precautions for use in animals
Do not inject into the subcutaneous fat.
Shake the vial well to obtain a homogenous solution.
Special precaution